{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-005673","form_type":"8-K","ticker":"MED","cik":"0000910329","company_name":"MEDIFAST INC","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.249990+00:00","generated_at":"2026-06-05T23:41:15.989772+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Medifast Q4 revenue falls 43% to $191M; guides Q1 2024 revenue $155-175M","bullets":["Q4 net income $6.0M ($0.55 diluted EPS); adjusted net income $11.9M ($1.09 adjusted EPS).","Active OPTA VIA Coaches down 32.5% YoY to 41,100; revenue per coach fell 16.1% to $4,648.","Full-year 2023 revenue $1.1B, down 32.9% YoY; net income $99.4M ($9.10 diluted EPS).","Q1 2024 revenue guidance $155-175M; diluted EPS $0.25-0.95, excluding LifeMD collaboration costs.","Cash and investments $150M, no interest-bearing debt; company pivoting to medically-supported weight loss with LifeMD."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-005673","json":"https://secwatch.observer/filing/0001628280-24-005673.json","markdown":"https://secwatch.observer/filing/0001628280-24-005673.md","text":"https://secwatch.observer/filing/0001628280-24-005673.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/910329/000162828024005673/0001628280-24-005673-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/910329/000162828024005673/med-20240220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T23:41:15.989772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"76669c90a4ed8d56d59930f57f51c8475b6d3c2a","claim":"MEDIFAST INC reported Full Year 2023 results: revenue $1.1 billion, net income $99.4 million, EPS $9.10.","evidence_excerpt":"Full Year 2023 • Revenue of $1.1 billion • Net income of $99.4 million (non-GAAP adjusted net income of $105.2 million) • EPS of $9.10 (non-GAAP adjusted EPS of $9.64)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/910329/000162828024005673/0001628280-24-005673-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2023"},{"label":"Revenue","value":"$1.1 billion"},{"label":"Net income","value":"$99.4 million"},{"label":"EPS","value":"$9.10"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7d7cc36bea198f530e1fc5f8107fff07ca72197d","claim":"MEDIFAST INC reported fourth quarter and full year ended December 31, 2023 results: revenue $191.0 million, net income $6.0 million, EPS $0.55 per diluted share.","evidence_excerpt":"Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTA VIA®, today reported results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 • Revenue of $191.0 million, with revenue per active earning Coach of $4,648 • Independent active earning OPTA VIA Coaches of 41,100 • Net income of $6.0 million (non-GAAP adjusted net income of $11.9 million) • Earnings per diluted share (\"EPS\") of $0.55 (non-GAAP adjusted EPS of $1.09) Full Year 2023 • Revenue of $1.1 billion • Net income of $99.4 million (non-GAAP adjusted net income of $105.2 million) • EPS of $9.10 (non-GAAP adjusted EPS of $9.64) • Cash, Cash Equivalents, and Investments of $150.0 million and no interest-bearing debt","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/910329/000162828024005673/0001628280-24-005673-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$191.0 million"},{"label":"Net income","value":"$6.0 million"},{"label":"EPS","value":"$0.55 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}